Clinical Trial

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Study acronym: CHANGE
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-12-26; most recent amendment 2026-03-25.
Status change: Not Yet Recruiting → Recruiting 2025-07-14
Trial Details
NCT Number NCT06757764
Lead Sponsor Asan Medical Center
Collaborators: Korea Otsuka Pharmaceutical Co., Ltd.
Conditions Cerebral Infarction, Stenosis Artery
Enrollment 2,340 participants
Start Date 2025-07-10
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-27